Furthermore, GLP-1 analogs, such as liraglutide, dulaglutide, and semaglutide, are now widely used in the clinic to treat patients with diabetes and obesity by various mechanisms, including anti-inflammation, emergency improvement, intestinal flora regulation, appetite suppression via the central nervous system, and weight reduction (121–123). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.